Clinical trials: Relapse Schizophrenia, open to volunteers
Psychotic Disorder
Speech-based Assessment of Relapse Risk in People With Psychosis
This observational, multinational study assesses the feasibility of speech and self-report data collection across six languages for Artificial Intelligence (AI)-driven relapse risk estimation in psychosis.
- Trial name
- TRUSTING-WP4 (NCT07397975)
- Testing
- Weekly online speech assessments via a smartphone app collect speech and self-report data. Recordings are securely transferred and analyzed by an AI-based backend to calculate relapse risk scores.
- Where
- 7 sites in Czechia, Ireland and 4 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Philipp Homan
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Relapse Management
Relapse Management Group Psychoeducation Program
This study was planned to be conducted between February and March 2026, with a total of 60 patients diagnosed with schizophrenia who met the inclusion criteria and were followed at the community mental health center in the…
- Trial name
- NCT07327944
- Testing
- Relapse Management Group Psychoeducation Program
- Volunteers
- 60 people
- Sponsor
- Ankara Etlik City Hospital
Patients With Schizophrenia
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia
Schizophrenia is a severe chronic mental disorder with a long-term treatment. Most antipsychotic (AP) drugs are effective for only 30% to 60% of patients and for many drugs, treatment selection remains a "trial-and-error"…
- Trial name
- PROMISE (NCT05839613)
- Testing
- Therapeutic Drug Monitoring (TDM) and Pharmacogenetics (PG)
- Volunteers
- 400 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
- Trial name
- NCT07686263
- Testing
- Xanomeline/Trospium Chloride
- Where
- 54 sites in United States, Argentina and 5 more
- Volunteers
- 472 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
The goal of this observational study is to learn whether changes in sleep can help identify early signs of relapse in adults with schizophrenia or bipolar disorder.
- Trial name
- DESCANT (NCT07921667)
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- International University of La Rioja
Schizophrenia
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.
- Trial name
- NCT07227818
- Testing
- NBI-1117568
- Where
- 25 sites in United States, Puerto Rico and 1 more
- Volunteers
- 560 people
- Sponsor
- Neurocrine Biosciences
Psychosis
Predicting Psychotic Relapse Using Speech-Based Early Detection
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability.
- Trial name
- MOTS+ (NCT06978894)
- Where
- 3 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Douglas Mental Health University Institute
Schizophrenia
Voice-Based Biomarkers: A Novel Approach to Monitoring and Predicting Schizophrenia Relapses
Schizophrenia is a serious psychiatric illness affecting approximately 25 million people worldwide. Patients with schizophrenia experience hallucinations, auditory illusions, disordered thinking, movement disorders, cognitive…
- Trial name
- OBSERVSPEECH (NCT06613334)
- Testing
- Blood test: measurement of plasma antipsychotic concentration, Voice interviews and questionnaires carried out via the CALLYOPE application
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier St Anne
Psychosis
Belief-updating, Speech and Psychosis
Psychotic illnesses are characterised by hallucinations, delusions, and disturbed thoughts; symptoms associated with high personal and societal costs.
- Trial name
- BASIS (NCT06042712)
- Volunteers
- 240 people
- Sponsor
- King's College London
Psychosis
A Pilot Trial of Tapering Antipsychotics for Patients in Remitted Psychosis Co-administering With N-Acetylcysteine
The investigators are going to observe if add-on of n-acetylcysteine (NAC) 1200 or 2400 mg/d during tapering of antipsychotics in patients with remitted psychosis can help to reduce the pre-requisite of stabilization to 3 months…
- Trial name
- NCT06546475
- Testing
- N-Acetylcysteine
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University